Leukemia Research
Volume 30, Issue 4 , Pages 449-457 , April 2006

Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma

  • Catherine A. Tucker

      Affiliations

    • The Department of Advanced Therapeutics, BC Cancer Research Center, 675 West 10th Avenue, 5th Floor, Vancouver, BC, Canada
    • The Department of Pathology and Laboratory Medicine at the University of British Columbia, Vancouver, BC, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 604 675 8000/7025; fax: +1 604 675 8183.
    • ,
  • Gwyn Bebb

      Affiliations

    • The Department of Advanced Therapeutics, BC Cancer Research Center, 675 West 10th Avenue, 5th Floor, Vancouver, BC, Canada
    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Richard J. Klasa

      Affiliations

    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Mukesh Chhanabhai

      Affiliations

    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Valia Lestou

      Affiliations

    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Douglas E. Horsman

      Affiliations

    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Randy D. Gascoyne

      Affiliations

    • Divisions of Medical Oncology and Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Adrian Wiestner

      Affiliations

    • Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Dana Masin

      Affiliations

    • The Department of Advanced Therapeutics, BC Cancer Research Center, 675 West 10th Avenue, 5th Floor, Vancouver, BC, Canada
    • ,
  • Marcel Bally

      Affiliations

    • The Department of Advanced Therapeutics, BC Cancer Research Center, 675 West 10th Avenue, 5th Floor, Vancouver, BC, Canada
    • The Department of Pathology and Laboratory Medicine at the University of British Columbia, Vancouver, BC, Canada
    • ,
  • Michael E. Williams

      Affiliations

    • Hematology/Oncology Division and Hematologic Malignancy Program, University of Virginia Cancer Center and School of Medicine, Charlottesville, VA, USA

Received 21 April 2005 ,Revised 11 August 2005 ,Accepted 12 August 2005.

References 

  1. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia. 1997;11:64–72
  2. Lai R, McDonnell TJ, O’Connor SL, Medeiros LJ, Oudat R, Keating M, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002;26:849–855
  3. M’Kacher R, Farace F, Bennaceur-Griscelli A, Violot D, Clausse B, Dossou J, et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet. 2003;143:32–38
  4. Rudolph C, Steinemann D, Von Neuhoff N, Gadzicki D, Ripperger T, Drexler HG, et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet Cytogenet. 2004;153:144–150
  5. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O’Connor SL, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003;127:424–431
  6. Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma. Leuk Res. 2002;26:781–787
  7. Saltman DL, Cachia PG, Dewar AE, Ross FM, Krajewski AS, Ludlam C, et al. Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. Blood. 1988;72:2026–2030
  8. Melo JV, Foroni L, Brito-Babapulle V, Luzzatto L, Catovsky D. The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol. 1988;73:23–28
  9. Abe M, Nozawa Y, Wakasa H, Ohno H, Fukuhara S. Characterization and comparison of two newly established Epstein–Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer. 1988;61:483–490
  10. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33:7–20
  11. Au WY, Gascoyne RD, Viswanatha DS, Connors JM, Klasa RJ, Horsman DE. Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymphoma. 2002;43:783–791
  12. Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell. 1994;79:573–582
  13. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487–3495
  14. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124–2130
  15. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197
  16. Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, et al. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998;22:341–353
  17. Dunn T, Praissman L, Hagag N, Viola MV. ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet. 1994;76:19–22
  18. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res. 2000;6:2492–2500
  19. Lestou VS, Gascoyne RD, Sehn L, Ludkovski O, Chhanabhai M, Klasa RJ, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol. 2003;122:745–759
  20. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink HK, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102:2568–2573
  21. Leenman EE, Panzer-Grumayer RE, Fischer S, Leitch HA, Horsman DE, Lion T, et al. Rapid determination of Epstein–Barr virus latent or lytic infection in single human cells using in situ hybridization. Mod Pathol. 2004;17:1564–1572
  22. Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47:195–201
  23. Taniwaki M, Nishida K, Ueda Y, Misawa S, Nagai M, Tagawa S, et al. Interphase and metaphase detection of the breakpoint of 14q32 translocations in B-cell malignancies by double-color fluorescence in situ hybridization. Blood. 1995;85:3223–3228
  24. Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, et al. Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer. 2005;42:164–169
  25. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011
  26. Rimokh R, Berger F, Bastard C, Klein B, French M, Archimbaud E, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994;83:3689–3696
  27. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM, Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995;10:1833–1840
  28. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102:1323–1326
  29. Decaudin D. Mantle cell lymphoma: a biological and therapeutic paradigm. Leuk Lymphoma. 2002;43:773–781
  30. Caligaris-Cappio F, Bergui L, Rege-Cambrin G, Tesio L, Migone N, Malavasi F. Phenotypic, cytogenetic and molecular characterization of a new B-chronic lymphocytic leukaemia (B-CLL) cell line. Leuk Res. 1987;11:579–588
  31. Ott MM, Bartkova J, Bartek J, Durr A, Fischer L, Ott G, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood. 1997;90:3154–3159
  32. Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed–Sternberg cells in Hodgkin lymphomas. Blood. 2004;103:2351–2357
  33. Iolascon A, Faienza MF, Coppola B, della Ragione F, Schettini F, Biondi A. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. Leukemia. 1996;10:255–260
  34. Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. Biochem Biophys Res Commun. 1998;247:146–153
  35. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol. 1997;8(Suppl. 2):71–73
  36. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000;19:3496–3506
  37. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12:2899–2911
  38. Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253–2261
  39. Arvanitakis L, Yaseen N, Sharma S. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol. 1995;155:1047–1056
  40. Sinclair AJ, Palmero I, Holder A, Peters G, Farrell PJ. Expression of cyclin D2 in Epstein–Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol. 1995;69:1292–1295
  41. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, et al. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene. 1994;9:1925–1929

PII: S0145-2126(05)00323-1

doi: 10.1016/j.leukres.2005.08.016

Leukemia Research
Volume 30, Issue 4 , Pages 449-457 , April 2006

Article Tools

* Image Usage & Resolution